Skip to main content

CMS looks to expand medicare coverage to CAR-T therapy

October 4, 2019

CMS plans to cover a specific kind of immunotherapy for cancer patients.

The Centers for Medicare & Medicaid Services revealed that it intends to allow Medicare to pay for chimeric antigen receptor (CAR) T-cell therapy, in which oncologists use a patient’s own immune system to attack a tumor.

The determination would require that Medicare cover CAR T-cell treatments across the country when it is offered in a registry or clinical study approved by the agency. CMS Administrator Seema Verma said in a statement that covering such therapies will allow CMS to gain deeper insight on how well it works for Medicare beneficiaries.

Get the Latest RCM News Delivered

Receive practical tips on medical billing and breaking news on RCM in your inbox.

Get in Touch